论文部分内容阅读
目前临床上使用的治疗肺动脉高压的内皮素受体拮抗剂通常通过阻断内皮素受体A或同时阻断内皮素A和B。理论上,从一个内皮素受体拮抗剂转用另一个进行治疗可能改变药物的不良反应或疗效。该研究探讨肺动脉高压患者从司他生坦转用安立生坦(两个主要的内皮素A受体拮抗剂)时对机体的影响作
Endothelin receptor antagonists currently used clinically to treat pulmonary hypertension generally block endothelin receptor A or block both endothelin A and B. Theoretically, switching from one endothelin receptor antagonist to another may change the side effects or the effects of the drug. This study examined the effects of stenting on the body in patients with pulmonary hypertension treated with anitrantic (the two major endothelin A receptor antagonists)